凯发一触即发

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Therapeutic Effects of FGF23 c‐tail Fc in a murine pre‐clinical model of X‐linked hypophosphatemia via the selective modulation of phosphate reabsorption.

J Bone Miner Res.. 2017-10; 
Johnson K,Levine K,Sergi J,Chamoun J,Roach R,Vekich J,Favis M,Horn M,Cao X,Miller B,Snyder W,Aivazian D,Reagan W,Berryman E,Colangelo J,Markiewicz V,Bagi CM,Brown TP,Coyle A,Mohammadi M,Magram J.
Products/Services Used Details Operation
... Stable cell line generation Plasmid construction for protein expression of Klotho were made by GenScript. Protein was ... Anti-HIS mouse mAb (GenScript Cat#A00186-100) was added alone and to each condition at 0.2ug/200uL in 3% BSA-PBS solution for one hour on ice. ...

摘要

Fibroblast growth factor 23 (FGF23) is the causative factor of X-linked hypophosphatemia (XLH), a genetic disorder effecting 1:20,000 that is characterized by excessive phosphate excretion, elevated FGF23 levels and a rickets/osteomalacia phenotype. FGF23 inhibits phosphate reabsorption and suppresses 1α,25-dihydroxyvitamin D (1,25D) biosynthesis, analytes that differentially contribute to bone integrity and deleterious soft-tissue mineralization. As inhibition of ligand broadly modulates downstream targets, balancing efficacy and unwanted toxicity is difficult when targeting the FGF23 pathway. We demonstrate that a FGF23 c-tail-Fc fusion molecule selectively modulates the phosphate pathway in vivo by competit... More

关键词

1,25D; FIBROBLAST GROWTH FACTOR 23; OSTEOMALACIA; PHOSPHATE; X-LINKED HYPOPHOSPHATEMIA